Xvivo Perfusion Q4: First impression

Research Note

2021-01-28

08:10

Redeye's first impressions on the Q4 results. Sales came in slightly lower than we expected at SEK 60.3m vs. our SEK 63.3m. The gross margin was lower than expected at 69% vs. our expectation of 77%. The deviations prove the low visibility at present and that the new business area Abdominal proved to have lower margins than we anticipated. We believe that sales will start to recover, while some uncertainty will persist during the first half of the current year. There was a gradual recovery that started in the third quarter but to which extent the pandemic will continue to affect intensive care units during 2021 remains to be seen.

MH

Mats Hyttinge

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.